美国Mineralocorticoid(f-hMR) 人盐皮质**受体可诱导表达细胞株
美国PrimCells诱导性稳定细胞株： PrimCells建立的独有的诱导性细胞高效开发系统，能在极短时间内筛选出低泄漏，高诱导性的稳定细胞株，成功开发出一系列核受体诱导表达的稳定细胞株产品，为多家知名制药公司研发部门和科研院所提供产品与服务，广受用户好评。针对客户的特定需求，PrimCells亦提供量身定制服务，通过密切的客户交流和高效的筛选体系，严格保证客户在3-4周内即获得高质量的诱导性稳定细胞株，具有市场其他供应商无可比拟的时效性。
Introduction:
Nuclear hormone receptors (NHRs) are a superfamily of transcription factors that function as powerful metabolic regulators to control a variety of systemic processes in physiology. They also play key roles in the pathophysiology of many major disease states, such as diabetes, obesity, inflammation, atherosclerosis and heart failure. To date, this superfamily has provided a rich source of drug design targets and it is continuing to be one of the hottest areas for pharmaceutical research. PrimCells now provides a comprehensive set of NHR expressing cell lines to the research community. These high-quality, flag- and/or HA-tagged NHR-expressing cell lines aim to facilitate further biochemical and molecular studies of their functions and hence encourage new strategies for drug design.
f-hMR/HEK293 cell line was created by stable co-transfection of HEK293 cells with two plasmids expressing the bacterial Tet repressor (TetR) and the human mineralocorticoid receptor (hMR) proteins. Since the hMR gene is driven by a promoter containing two tetracycline operator (TeTO2) sites, the expression of hMR protein can be induced by doxycycline.
Figure 1 | Confirmed hMR Expression in f-hMR stable cells
美国PrimCells品牌介绍
PrimCells是位于美国加州圣迭戈的一家专业致力于细胞产品研发和解决方案提供的业内技术领导企业。
公司汇集了**的生物医药技术专家，独立开发了多项原代细胞和干细胞相关的专有技术。 公司以“细胞研究的选择”为宗旨，自主研发超过70种**产品，填补了多个特种细胞市场的空白。例如其诱导性表达细胞库和高效3D皮肤培养系统，皆为该类产品目前市场上少数的规模化供应商。此外，公司以高质量的数据与快速稳定的项目完成时间，长期为多家知名制药公司提供解决方案，获得用户广泛赞誉。
PrimCells产品线：
-
报告基因干细胞 2. 原代细胞（含报告基因原代细胞） 3. 诱导性稳定细胞株
4. 人源重组蛋白 5. **型培养试剂
PrimCells 解决方案
1.诱导性稳定细胞株开发 2. 原代细胞开发 3. **体外毒理和效能测试 4. 3D-皮肤培养
PrimCells合作伙伴及客户:
A．生物制药公司：辉瑞(Pfizer), 诺华(Novartis), 礼来(Eli2 Lilly),. Amgen, EMD Millipore, Regeneron等公司的毒理和医药研发部门
B．科研机构：冷泉港实验室，哈佛医学院, 麻省理工（MIT）,， UCSF, NYU, Salk, UIUC, USC等
